文献速递外周动脉疾病

准分子激光斑块旋切术治疗复杂股腘动脉支架内再狭窄

The Endovascular Therapy Using Excimer Laser Atherectomy for Complex Femoropopliteal In-Stent Restenosis Lesions.
PubMed 文献 · J Endovasc Ther · 2025-08-20

本研究为回顾性多中心注册分析,纳入2020至2024年因股腘动脉支架内再狭窄接受准分子激光斑块旋切术(ELA)行腔内治疗(EVT)的166例患者。技术成功率为83.7%,1年免于再狭窄的Kaplan-Meier估计为67.6%(95%CI 60.0-75.5)。

要点

  • ELA治疗股腘动脉ISR技术成功率83.7%,但1年免于再狭窄率仅67.6%。
  • EVT完成造影慢血流与透析依赖慢性肾衰独立增加再狭窄风险。
  • 合并1或2个危险因素者1年免于再狭窄率仅46.6%,无危险因素者为77.8%。

核心结论

  • ELA在当前的股腘动脉ISR病变中提供了可接受的技术成功率,但长期结果在临床上欠理想。

研究设计与样本

  • 回顾性多中心注册分析,纳入2020至2024年因股腘动脉ISR病变接受ELA行EVT的连续166例患者。

主要发现

  • 支架内闭塞占88.6%,非裸金属支架(BMS)相关ISR占52.4%。
  • 技术成功率为83.7%。
  • 1年免于再狭窄的Kaplan-Meier估计为67.6%(95%CI 60.0-75.5)。
  • 主要辅助通畅率和二期通畅率分别为72.7%(95%CI 65.8-80.3)和81.5%(95%CI 76.6-88.0)。

关键数值与推荐

  • 合并1或2个危险因素亚组的1年免于再狭窄Kaplan-Meier估计为46.6%,无危险因素者为77.8%。
  • BMS相关ISR与药物洗脱支架相关ISR的1年主要通畅率Kaplan-Meier估计相当。

临床怎么用

  • ELA可用于股腘动脉ISR的腔内治疗,但需告知患者长期通畅率欠理想。
  • 对EVT完成造影显示慢血流或透析依赖慢性肾衰的患者,应加强随访并考虑更积极的再狭窄防控策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The guidelines recommend excimer laser atherectomy (ELA) for in-stent restenosis (ISR) lesions in femoropopliteal arteries. However, its efficacy is still unknown in ISR related to scaffolds other than bare-metal stent (BMS). This study aimed to evaluate the 1-year clinical outcomes in patients with femoropopliteal ISR lesions treated with endovascular therapy (EVT) using ELA. MATERIALS AND METHODS: This retrospective multicenter registry analyzed patients who presented with peripheral artery disease caused by femoropopliteal ISR lesions undergoing EVT with ELA between 2020 and 2024. The primary outcome was re-restenosis 1-year following EVT. RESULTS: Overall, consecutive 166 patients with femoropopliteal ISR lesions were enrolled. The rates of in-stent occlusion and ISR related to scaffolds other than BMS were found in 88.6% and 52.4% of the lesions, respectively. Technical success was achieved in 83.7%. The 1-year Kaplan-Meier estimate of freedom from re-restenosis was 67.6% (95% confidence interval [CI] 60.0-75.5). The primary-assisted patency and secondary patency rate was 72.7% (95% CI 65.8-80.3) and 81.5% (95% CI 76.6-88.0), respectively. In the multivariate analysis, slow flow observed in the completion angiography of EVT (adjusted hazard ratio, 2.32; P = .024) and chronic renal failure requiring dialysis (1.72; P = .036) were independently associated with re-restenosis risk. The accumulation of these factors was associated with a lower rate of freedom from re-restenosis; Kaplan-Meier estimates of the rates were 46.6% in subgroups with 1 or 2 risk factors, whereas it was 77.8% in the absence of risk factors. The Kaplan-Meier estimate shows a comparable primary patency rate between ISR related to BMS and drug-eluting stent at 1 year. CONCLUSION: ELA provided acceptable technical success in current femoropopliteal ISR lesions; however, the long-term result was clinically suboptimal.Clinical ImpactThis retrospective multicenter registry enrolled 166 patients with in-stent restenosis/in-stent occlusion lesions in femoropopliteal arteries treated with endovascular therapy using excimer laser atherectomy. The technical success rate was acceptable at 83.7%; however, 1-year estimate of freedom from restenosis was clinically suboptimal at 67.6%. The multivariate analysis showed incomplete antegrade blood flow and dialysis-dependent chronic renal failure were independently associated with re-restenosis risk.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Horie K, Takahara M, Takiuchi S, et al. The Endovascular Therapy Using Excimer Laser Atherectomy for Complex Femoropopliteal In-Stent Restenosis Lesions. J Endovasc Ther. 2025. PMID: 40832841. doi:10.1177/15266028251363466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。